Published in Hepatology on June 01, 2010
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut (2014) 2.33
Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A (2010) 1.67
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One (2011) 1.27
Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virol J (2011) 1.23
Effects of silybum marianum on patients with chronic hepatitis C. J Res Med Sci (2011) 1.15
Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol (2012) 1.08
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther (2012) 1.07
Silymarin for HCV infection. Antivir Ther (2012) 1.04
Hepatitis C virus and natural compounds: a new antiviral approach? Viruses (2012) 1.03
Antioxidants as therapeutic agents for liver disease. Liver Int (2011) 1.02
Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology (2013) 1.02
Absolute configuration of isosilybin A by X-ray crystallography of the heavy atom analogue 7-(4-Bromobenzoyl)isosilybin A. J Nat Prod (2012) 0.96
New hepatitis C therapies in clinical development. Eur J Med Res (2011) 0.96
Antiviral activity of silymarin against chikungunya virus. Sci Rep (2015) 0.93
Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One (2011) 0.93
Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. Virology (2012) 0.92
Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med (2010) 0.91
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90
Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star Alloeocomatella polycladia. Mar Drugs (2012) 0.89
Enhanced bioactivity of silybin B methylation products. Bioorg Med Chem (2012) 0.87
Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis (2013) 0.87
Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Alternat Med (2012) 0.86
Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved. Hepatology (2011) 0.86
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. PLoS One (2012) 0.86
Phylogenetic and chemical diversity of fungal endophytes isolated from Silybum marianum (L) Gaertn. (milk thistle). Mycology (2015) 0.85
Entry inhibitors: New advances in HCV treatment. Emerg Microbes Infect (2016) 0.84
Quercetin and quercetin 3-O-glycosides from Bauhinia longifolia (Bong.) Steud. show anti-Mayaro virus activity. Parasit Vectors (2014) 0.84
Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling. J Nat Prod (2015) 0.83
Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab Invest (2014) 0.83
Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci (2015) 0.81
Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother (2012) 0.81
Silymarin content in Silybum marianum populations growing in Egypt. Ind Crops Prod (2016) 0.80
Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. Virol J (2013) 0.80
Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol (2016) 0.80
Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int (2014) 0.79
Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection. Viruses (2015) 0.79
Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp. PLoS One (2012) 0.78
Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. World J Hepatol (2014) 0.78
Manganese induces oxidative stress, redox state unbalance and disrupts membrane bound ATPases on murine neuroblastoma cells in vitro: protective role of silymarin. Neurochem Res (2011) 0.78
Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism. Virology (2013) 0.78
Interplay between Hepatitis C Virus and Redox Cell Signaling. Int J Mol Sci (2013) 0.78
Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C infection: an exploratory study. Indian J Pharmacol (2015) 0.78
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol (2011) 0.78
Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection. J Viral Hepat (2013) 0.77
Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention. Nucleic Acids Res (2014) 0.77
Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res (2014) 0.76
Dehydrosilybin attenuates the production of ROS in rat cardiomyocyte mitochondria with an uncoupler-like mechanism. J Bioenerg Biomembr (2010) 0.76
Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds. PLoS One (2015) 0.76
In silico studies of medicinal compounds against hepatitis C capsid protein from north India. Bioinform Biol Insights (2014) 0.75
Free Radical Scavenging and Antioxidant Activities of Silymarin Components. Antioxidants (Basel) (2013) 0.75
Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection. Antimicrob Agents Chemother (2016) 0.75
Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J Viral Hepat (2016) 0.75
Hepatitis C virus management: potential impact of nanotechnology. Virol J (2017) 0.75
Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells. PLoS One (2017) 0.75
Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food Supplements. Antioxidants (Basel) (2013) 0.75
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol (2007) 8.98
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J Virol (2004) 2.76
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology (2008) 2.62
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology (2008) 2.45
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol (2007) 2.41
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology (2007) 1.85
Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther (2007) 1.76
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology (2009) 1.69
Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med (2007) 1.61
Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res (2005) 1.45
Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol (2007) 1.44
Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem (2005) 1.41
Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology (2009) 1.40
Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One (2009) 1.31
Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos (2007) 1.31
Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol (2003) 1.29
Silibinin protects mice from T cell-dependent liver injury. J Hepatol (2003) 1.23
An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed (2008) 1.14
Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol (2003) 1.14
Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene (2002) 1.14
Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J (2005) 1.08
Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology (1995) 1.05
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05
Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther (2007) 1.04
Investigations on the binding and antioxidant properties of the plant flavonoid fisetin in model biomembranes. FEBS Lett (2004) 1.03
Milk thistle. Am Fam Physician (2005) 0.99
Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry (2007) 0.96
Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid. J Lipid Res (2000) 0.94
Characterization of Pichinde virus infection of cells of the monocytic lineage. J Virol (1991) 0.90
Silymarin as a potential hypocholesterolaemic drug. Physiol Res (1998) 0.87
Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. J Viral Hepat (2009) 0.85
The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung (1975) 0.79
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med (2010) 7.11
Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature (2008) 6.25
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol (2003) 5.41
Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol (2002) 5.21
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A (2002) 3.43
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
Quantitative analysis of the hepatitis C virus replication complex. J Virol (2005) 2.91
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology (2002) 2.55
Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology (2002) 2.53
The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology (2010) 2.52
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology (2008) 2.50
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Assembly of infectious hepatitis C virus particles. Trends Microbiol (2010) 2.36
Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle (2009) 2.30
Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol (2007) 2.29
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation (2008) 2.22
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest (2008) 2.08
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Discovery of anticancer agents of diverse natural origin. Pure Appl Chem (2009) 2.00
A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods (2003) 1.96
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med (2005) 1.93
Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium. Stem Cells (2007) 1.93
Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells (2008) 1.90
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships. J Nat Prod (2011) 1.81
Quantum dot imaging for embryonic stem cells. BMC Biotechnol (2007) 1.78
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J (2013) 1.77
Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther (2007) 1.76
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod (2011) 1.69
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A (2010) 1.67
Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology (2011) 1.64
Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology (2008) 1.64
Self-assembling elastin-like peptides growth factor chimeric nanoparticles for the treatment of chronic wounds. Proc Natl Acad Sci U S A (2010) 1.63
Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication. J Biol Chem (2005) 1.63
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med (2007) 1.61
Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res (2005) 1.61
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
New colchicinoids from a native Jordanian meadow saffron, colchicum brachyphyllum: isolation of the first naturally occurring dextrorotatory colchicinoid. J Nat Prod (2005) 1.59
Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem (2003) 1.58
Survivin: a novel player in insulin cardioprotection against myocardial ischemia/reperfusion injury. J Mol Cell Cardiol (2010) 1.58
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Positron emission tomography imaging of conditional gene activation in the heart. J Mol Cell Cardiol (2007) 1.56
The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J Virol (2002) 1.56
Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine (2008) 1.54
Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem (2011) 1.54
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem (2005) 1.54
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) (2011) 1.52
HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case. J Org Chem (2013) 1.52
Confinement to organelle-associated inclusion structures mediates asymmetric inheritance of aggregated protein in budding yeast. Cell Rep (2012) 1.52
Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J (2005) 1.52
Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology (2012) 1.49
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Use of complementary and alternative medicine for the treatment of genital herpes. Herpes (2005) 1.48
Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol Ther (2010) 1.47
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev (2008) 1.46